A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples

The clinically tested KCa3.1 channel blocker, senicapoc, has been proven to have excellent pharmacological properties and prior clinical trials found it to be safe for use in patients with sickle cell anaemia. Currently, several preclinical projects are aiming to repurpose senicapoc for other indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sørensen, Lambert K., Petersen, Asbjørn, Granfeldt, Asger, Simonsen, Ulf, Hasselstrøm, Jørgen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869607/
https://www.ncbi.nlm.nih.gov/pubmed/33626443
http://dx.doi.org/10.1016/j.jpba.2021.113956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869607/
https://www.ncbi.nlm.nih.gov/pubmed/33626443
http://dx.doi.org/10.1016/j.jpba.2021.113956

Ejemplares similares